Vertex Pharmaceuticals to Rely on Acquisitions to Diversify Its Business
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals (VRTX) - Get Vertex Pharmaceuticals Incorporated Report will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis. That's the assessment from Ian Smith, the company's chief financial officer. The comments were made at the J.P. Morgan Healthcare Conference. There are a few areas that Vertex may explore, including sickle cell disease and Huntington's disease. "We, of course, look at everything in cystic fibrosis," said Smith, in an interview at the conference. "But we also have an interest in diversifying the pipeline beyond cystic fibrosis."
Scroll to Continue
